DGK Frühjahrstagung, 04.-07. April 2018 Kongresshallen Rosengarten, Mannheim

# Niels-Stensen-Kliniken Marienhospital Osnabrück

### **Symposium: Rare Diseases:**

**Underdiagnosed and undertreated?** 



# **ARVC:** Arrhythmogenenic Right Ventricular Cardiomyopathy

#### **Thomas Wichter, MD, FESC**

**Professor of Medicine (Cardiology)** 

Klinik Innere Medizin / Kardiologie

Herzzentrum Osnabrück - Bad Rothenfelde

Niels-Stensen-Kliniken Marienhospital Osnabrück Germany






### **Conflict of Interest - Disclosure**


I, Thomas Wichter, DO NOT have a financial interest / arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

# What is ARVC? Be aware of clinical features


- Young, apparently healthy pts
- Ventricular arrhythmias (LBBB pattern)
- **Exercise provocable arrhythmias**
- High prevalence in athletes
- Family history (ARVC, unexplained SCD)
  - Genetic background (desmosomal proteins)
- Right precordial ECG abnormalities
  - T-wave inversion, QRS prolongation, ε-waves
- RV-enlargement / RV-dysfunction
- LV involvement possible (even dominant)





















#### What awareness can do ...



#### **Preparticipation Screening of Athletes**

4-fold Reduction of Sudden Death in Athletes in Italy by Disqualification of diagnosed HCM and ARVC pts



## **Epidemiology of ARVC**



- First descriptions date back to 18th century
- Rare disease (1:2000 to 1: 5000, underestimated?)
- Regional clustering (genetic reasons; i.e. Veneto)
- Difficult, multifactorial diagnosis (integrative approach)
- Mild or incomplete disease manifestation (expressivity)
- Silent or subclinical mutation carriers (penetrance)
- Selection bias results in different ARVC populations (primary vs. tertiary or arrhythmia vs. heart failure vs. genetic centres) with respect to prevalence, expression and prognosis

### Underdiagnosed .....?



- ... False Negatives (Specificity high, Sensitivity low)
- Increased risk of sudden death due to undertreatment

#### Overdiagnosed .....?

- ... False Positives (Specificity low, Sensitivity high)
- Disease "labeling" (incl. family members)
  potential consequences for social life, sports activity, insurances, etc.
- Unjustified ICD indications (incl. complications, inappr. shocks)

### Misdiagnosed .....?

- other diseases mimicking ARVC remain unrecognized (myocarditis, sarcoidosis, cardiomyopathies, etc.)
- ... specific treatment options not applied

#### **Limitations of Evidence**



- Rare disease, no diagnostic gold standard
- Integrated multi-modality diagnostic approach
- Diagnostic Criteria (Internat. Task Force 2010), modified to increase accuracy by gain in sensitivity without loss of specificity
  - Wall motion and structure (RV / LV: global + regional)
  - Tissue characterization of walls (histopathology)
  - ECG depolarization (QRS prolongation, epsilon-potential)
  - ECG repolarization (T-wave inversion)
  - Arrhythmias (LBBB-VT, exercise-induced)
  - Genetics / family history (mutations in desmosomal genes)
- Treatment based on personal experience, consensus and individual decisions rather than evidenced data

# **Diagnostic Criteria of ARVC**International ARVC Task Force (2010)





European Heart Journal doi:10.1093/eurheartj/ehg025 SPECIAL REPORT

# Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia

Proposed Modification of the Task Force Criteria

Frank I. Marcus<sup>1\*</sup> Chair, William J. McKenna<sup>2</sup> Co-Chair, Duane Sherrill<sup>1</sup>, Cristina Basso<sup>3</sup>, Barbara Bauce<sup>3</sup>, David A. Bluemke<sup>4</sup>, Hugh Calkins<sup>5</sup>, Domenico Corrado<sup>3</sup>, Moniek G.P.J. Cox<sup>6</sup>, James P. Daubert<sup>7</sup>, Guy Fontaine<sup>10</sup>, Kathleen Gear<sup>1</sup>, Richard Hauer<sup>6</sup>, Andrea Nava<sup>3</sup>, Michael H. Picard<sup>11</sup>, Nikos Protonotarios<sup>13</sup>, Jeffrey E. Saffitz<sup>12</sup>, Danita M. Yoerger Sanborn<sup>11</sup>, Jonathan S. Steinberg<sup>9</sup>, Harikrishna Tandri<sup>5</sup>, Gaetano Thiene<sup>3</sup>, Jeffrey A. Towbin<sup>14</sup>, Adalena Tsatsopoulou<sup>13</sup>, Thomas Wichter<sup>15</sup>, and Wojciech Zareba<sup>8</sup>


Marcus FI et al. Circulation. 2010;121:1533-1541 and Eur Heart J. 2010;31:806-814


### **Diagnostic Criteria of ARVC**

#### **International ARVC Task Force (2010)**



#### **Genetics and Family History**






**Ventricular Arrhythmias (LBBB-VT)** 




ECG: Depolarization + Repolarization







**Tissue Characterization** 




**Pathology** 



**RV-/LV- Wall Motion + Structure** 



#### **Case-1: Cardiac Arrest**






- 31 yr.-old man, athlete
- Cardiac arrest during soccer
- SR after 1° defibrillation
- ROSC and stable rhythm
- Family history of SCD


**Diagnosis: ARVC** 

#### **Case-1: Cardiac Arrest**






- 31 yr.-old man, athlete
- Cardiac arrest during soccer
- SR after 1° defibrillation
- ROSC and stable rhythm
- Family history of SCD




**Diagnosis: ARVC** 

#### **Case-1: Cardiac Arrest**






- 31 yr.-old man, athlete
- Cardiac arrest during soccer
- SR after 1° defibrillation
- ROSC and stable rhythm
- Family history of SCD




**Diagnosis: ARVC** 

# Reassess: Is it really ARVC? Or is it rather ...?











**Cardiac Sarcoidosis** 

**Restrictive CM** 

**Idiopathic RVO-VT** 

Make the correct diagnosis for specific therapy!





Myocarditis (acute / chronic)

## Making the Correct Diagnosis Niels-Stensen-Kliniken



- Detailed diagnostic evaluation (multi-modality approach)
- Appropriate test protocols for ARVC diagnosis ECG speed and filters, Angio projections, Echo views on RV, MRI protocol and sequences, target-directed biopsy, 3D EP-Mapping
- Avoid bias when indicating tests (question triggers answer)
- Expert reading and interpretation of findings
- Genetic testing for identification of affected relatives

  Confirmatory testing controversial (diagnosis and risk stratification)

  Proband: Negative psychological + social impact may outweigh clinical value Family: Cascade screening helps to identify subjects at risk
- Balanced and experienced clinical evaluation Counselling and recommendations for management of ARVC (incl. families)

# **Arrhythmias in ARVC:** Unique VT substrate



- Familial, genetic basis (desmosomal proteins)
- Broad spectrum of clinical VA (PVC, syncope, VT, VF)
- Phasic clinical stages (natural history)
- Exercise modification (penetrance, expression, aggravation)
- Progressive (exercise, competitive sports, inflammation, etc.)
- Multifocal (RV, LV)
- Predilection areas (RVOT, apex, RV-inflow)
- Pleomorphic (multiple VT morphologies, mostly LBBB)
- Epicardial location (mapping + ablation)

### **ECG** Diagnostics



#### Most important screening tool in ARVC!


- Inverted T-waves in right precordial leads (V₁-V₃)
  - Normal in children <14 yrs., only 1% in normal older individuals</li>
  - 60-95% prevalence in ARVC (major diagnostic criterion)
  - Near 100% sensitivity when combined with LBBB-VT
  - Extent relates to degree of RV involvement in ARVC
- QRS prolongation in right precordial leads (V<sub>1</sub>-V<sub>3</sub>)
  - Conduction delay over RV (arrhythmogenic substrate)
  - QRS >110 ms, S-wave >55 ms are sensitive markers of ARVC
- Epsilon wave (potential) in right precordial leads (V<sub>1</sub>-V<sub>3</sub>)
  - Low amplitude signal after the end of QRS
  - Mainly present in severe manifestations of ARVC
  - High interobserver variability (no added value without other ARVC criteria)

# **ECG:** Epsilon-Potential

Epsilon wave after the end of QRS in  $V_{1-3}$ , separated from QRS by isoelectrical interval




Platonov PG, ..., Wichter T,..., et al. Heart Rhythm.2015



# **ECG:** Epsilon-Potential

Main message: diagnostic impact was low (no added value).

Caution in assessment when pts do not otherwise fulfill criteria



Platonov PG, ..., Wichter T,..., et al. Heart Rhythm.2015

## Cardiac Imaging



- RV evaluation by imaging remains difficult
  - Despite enormous improvement in imaging technology
  - Complex RV structure, shape and wall motion (non-symmetrical)
- MRI depicts wall structure, motion + tissue
  - Fatty infiltration alone is not a sufficient criterion
  - Fibrofatty replacement + abnormal regional wall motion = diagnostic
- Appropriate imaging protocols and expert reading
  - Multimodal diagnostic approach
  - Standardized imaging protocols and quantitative analysis
  - Interpretation by experts in imaging and ARVC
- High degree of inter-observer variability
  - Incorrect MRI interpretation is a frequent cause of overdiagnosing!

### Ask Questions, get Answers



- Dx: Idiopathic RV Outflow-Tract Tachycardia (RVO-VT)
- Q: "Clinical suspect of ARVC. Fibrofatty replacement of myocardium? Wall motion abnormalities?"
- A: "Findings well compatible with ARVC, but nonspecific: prominent trabeculation, epicardial fat and fibrosis, mainly over RV free wall"
- Dx: ARVC with LV involvement
- Q: "Unexplained syncope and palpitations. Structural abnormalities of the heart?"
- A: "Nonspecific diffuse myocardial damage, DD: mild dilative CMP (DCM), chronic myocarditis"

# Genetic Background + Testing Niels-Stensen-Kliniken




- Gene mutations in 60-70% of ARVC
- Desmosomal genes affected
  - Cell contact, adhesion and signal transduction
- Autosomal-dominant genetic trait
  - Reduced penetrance (silent gene carriers)
  - Variable expressivity (disease manifestation and severity)
  - Modifier genes and exogenic factors
  - Digenic or compound mutations (5-20%) may impact severity
  - Genetic polymorphism (non-specific): up to 20% of normal controls
- Genetic counseling mandatory
- Genetic testing controversial
  - Confirmatory testing rarely impacting diagnosis + risk assessment
  - Proband: usually no consequence or added benefit, but allows ...
  - ... Cascade screening: to identify / exclude gene-affected relatives

#### **ARVC**

### **Genetic Disposition**



Double/compound mutations, modifier genes




Wichter T et al. in Marcus FI, Nava A, Thiene G (eds.), Springer Verlag. 2008, page 147

#### **Natural Course of ARVC**



- Risk of VF or fast VT: early (concealed) phase (arrhythmias may precede morphological abnormalities)
- Recurrent monomorphic VT: overt phase
- Chronic biventricular heart failure: end-stage





Aziz et al., Circulation. 2000;101;825-827

Wichter T et al., 2005

# Case-2: Asymptomatic nsVT male, age 14



- **Symptom:** presyncope (vasovagal?)
- Sports: competitive (football)
- Family history: 1 questionable case
- Genetic test: nonspecific, Desmoplakin polymorphism
- **ECG:** normal 12-lead and SAECG negative T in V1-V2
- **Exercise Test:** 1x nsVT (5 sec, 165 bpm)
- **Echo:** mild LV dilatation, normal RV
- MRI: normal RV + LV, no fat, no LGE
- EP-Study: normal, no WPW, no SVT or VT/VF inducible



## Case-2: Asymptomatic nsVT male, age 14



- **Symptom:** presyncope (vasovagal?)
- Sports: competitive (football)
- Family history: 1 questionable case
- Genetic test: nonspecific, Desmoplakin polymorphism
- ECG: normal 12-lead and SA negative T in V1-V2
- **Exercise**
- What risk?
- ร์VT or VT/VF inducible no V





# Case-2: Asymptomatic nsVT

nsVT 5 sec (165 bpm, LBBB, inferior axis) asymptomatic during treadmill stress test



#### **Resting ECG during SR**






#### Risk Stratification in ARVC

#### Role of Syncope, nsVT, Family History



ICD intervention-free survival in prim. prevention ICD cohort



#### **Appropriate ICD-Tx:**

VT at PVS: p = 0.98

RV  $\downarrow$  (diffuse): p = 0.84

Family Hx: p = 0.14

Age < 35: p = 0.07

nsVT: p = 0.03

Syncope: p = 0.008

DARVIN-2 Registry.
Corrado D et al.
Circulation. 2010;122:1144

# Case-2: Asymptomatic nsVT male, athlete, age 14



- **Symptom:** presyncope (vasovagal?)
- Sports: competitive (football)
- Family history: 1 questionable case
- Genetic test: nonspecific, Desmoplakin polymorphism
- **ECG:** normal 12-lead and SAECG negative T in V1-V2
- **Exercise Test:** 1x nsVT (5 sec, 165 bpm)
- **Echo:** mild LV dilatation, normal RV
- MRI: normal RV + LV, no fat, no LGE
- EP-Study: normal, no WPW, no SVT or VT/VF inducible



# Case-2: Asymptomatic nsVT male, athlete, age 14



- Symptom: presynce
  Sports:
  Facilitator

  Periodical and SAECG
  In V1-V2
- Exercise Test: 1x nsVT (5 sec, 165 bpm)
- **Echo:** mild LV dilatation, normal RV
- MRI: normal RV + LV, no fat, no LGE
- EP-Study: normal, no WPW, no SVT or VT/VF inducible



# Case-2: Asymptomatic nsVT Niels-Stensen-Kliniken Warienhospital Osnabrück Clinically relevant questions:

- Is this ARVC (no structural disease detected) ?
- Was genetic testing useful?
- Should this 14 yr-old boy be labelled with a disease ?
  - Issues of psychology, quality of life, insurances, etc.
- What is the prognosis?

# My personal (!) decision:

Low-dose beta-blockers
Recreational sports o.k. (non-competitive!)
Watchful waiting and reevaluation
Final diagnosis left open



#### **Risk Stratification in ARVC**

### Management of ARVC



European Heart Journal Advance Access published July 27, 2015




European Heart Journal doi:10.1093/eurheartj/ehv162 **CURRENT OPINION** 

# Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement

Domenico Corrado<sup>1\*</sup>, Thomas Wichter<sup>2</sup>, Mark S. Link<sup>3</sup>, Richard Hauer<sup>4</sup>, Frank Marchlinski<sup>5</sup>, Aris Anastasakis<sup>6</sup>, Barbara Bauce<sup>1</sup>, Cristina Basso<sup>1</sup>, Corinna Brunckhorst<sup>7</sup>, Adalena Tsatsopoulou<sup>8</sup>, Harikrishna Tandri<sup>9</sup>, Matthias Paul<sup>10</sup>, Christian Schmied<sup>7</sup>, Antonio Pelliccia<sup>11</sup>, Firat Duru<sup>7</sup>, Nikos Protonotarios<sup>8</sup>, NA Mark Estes III<sup>3</sup>, William J. McKenna<sup>12</sup>, Gaetano Thiene<sup>1</sup>, Frank I. Marcus<sup>13</sup>, and Hugh Calkins<sup>9</sup>


Eur Heart J. 2015;36: online July 27



#### **Risk Stratification in ARVC**

#### **ICD Indication in ARVC**





Corrado D, Wichter T, et al. Eur Heart J. 2015 and Circulation 2015; online July 27, 2015

#### **Provocative Statement**



- We should be the patient's "medical lawyer"
  - Correct diagnosis, best counseling, appropriate therapy
  - Personalized medicine according to data and experience
  - Prevention of sudden death
  - Improvement in quality of life
  - Avoid overdiagnosing with psychological + social impact
- We should not become our own "defence lawyer"
  - Decisions and counseling not driven by medicolegal aspects
  - Doctor's peace of conscience
  - Fear of malpractice lawsuits
  - "Treat the patient, not ourselves" (by pseudo-safety decisions)

### **Take-Home Messages**



- Be aware of ARVC signs + symptoms ("could it be ARVC?")
- Avoid underdiagnosing and undertreatment (SCD risk)
- Perform detailed diagnostic examination
- Assure expert reading + interpretation of tests
- Make the correct diagnosis (Task Force Criteria 2010)
- Think twice before you recommend genetic testing
  - Clear consequences, integration into clinical management
- Reassure ARVC, check for DD ("is it really ARVC?")
- Avoid overdiagnosing ("false labeling" and ICD "overtreatment")
- Individual, personalized treatment decisions

DGK Frühjahrstagung, 04.-07. April 2018 Kongresshallen Rosengarten, Mannheim



#### **Symposium: Rare Diseases:**

**Underdiagnosed and undertreated?** 



# **ARVC:** Arrhythmogenenic Right Ventricular Cardiomyopathy

#### **Thomas Wichter, MD, FESC**

**Professor of Medicine (Cardiology)** 

Klinik Innere Medizin / Kardiologie

Herzzentrum Osnabrück - Bad Rothenfelde

Niels-Stensen-Kliniken Marienhospital Osnabrück Germany

